EMA encourages companies to submit type I variations for 2023 in November 2023
Submitted by Anonymous (not verified) on 3 November 2023 - 14:48
EMA encourages companies to submit type I variations for 2023 in November 2023
Final Minutes – HMA-EMA joint Big Data Steering Group teleconference
Submitted by Anonymous (not verified) on 3 November 2023 - 14:32
Final Minutes – HMA-EMA joint Big Data Steering Group teleconference
PRIME: priority medicines
Submitted by Anonymous (not verified) on 3 November 2023 - 14:27
PRIME: priority medicines
Call for expression of interest for independent scientific experts to participate in the work of EMA’s Safety Committee
Submitted by Anonymous (not verified) on 3 November 2023 - 14:00
Call for expression of interest for independent scientific experts to participate in the work of EMA’s Safety Committee
Call for expressions of interest for patients’ organisations representatives to join Committee for Orphan Medicinal Products (COMP)
Submitted by Anonymous (not verified) on 3 November 2023 - 14:00
Call for expressions of interest for patients’ organisations representatives to join Committee for Orphan Medicinal Products (COMP)
Scientific publications
Submitted by Anonymous (not verified) on 3 November 2023 - 10:35
Scientific publications
Clinical requirements for non replacement therapy in haemophilia A and B - Scientific guideline
Submitted by Anonymous (not verified) on 31 October 2023 - 16:37
Clinical requirements for non replacement therapy in haemophilia A and B - Scientific guideline
Influenza vaccines - non-clinical and clinical module - Scientific guideline
Submitted by Anonymous (not verified) on 31 October 2023 - 16:30
Influenza vaccines - non-clinical and clinical module - Scientific guideline
Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline
Submitted by Anonymous (not verified) on 31 October 2023 - 16:28
Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline
Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 14/10/1998, Revision: 49, Status: Authorised
Submitted by Anonymous (not verified) on 31 October 2023 - 16:06
Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 14/10/1998, Revision: 49, Status: Authorised